Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
Two hundred thirty-seven Ghanaian human immunodeficiency virus-infected patients who were starting antiretroviral therapy underwent clinical and immunological monitoring for 3 years. Seventy-eight percent of patients had disease classified as World Health Organization stage III or IV. The mean increase in the CD4 cell count was 395 cells/mm(3), 13% of patients experienced immunological failure, and 8% of patients switched treatment to a second-line regimen. However, two-thirds of patients who experienced immunological failure did not switch treatment, and 31% of all patients were lost to follow-up.
Collini
Paul
P
School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom. P.Collini@sheffield.ac.uk
Schwab
Uli
U
Sarfo
Stephen
S
Obeng-Baah
Joseph
J
Norman
Betty
B
Chadwick
David
D
Bibby
David
D
Bedu-Addo
George
G
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D005869:Ghana; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
D019380:Anti-HIV Agents